Overview
Immutep Limited is an Australian biotechnology company that specializes in the development of immunotherapy treatments for cancer and autoimmune diseases. Founded in 1987 and headquartered in Sydney, Immutep is at the forefront of advancing immunotherapeutic products that harness the body’s immune system. Its key projects focus on the proprietary LAG-3 (Lymphocyte Activation Gene-3) technology, which has yielded multiple product candidates, including eftilagimod alpha (IMP321), positioned as a potential enhancer of the immune response to various tumors. Additionally, Immutep’s pipeline includes multiple partnerships with major pharmaceutical companies aimed at co-developing and commercializing their immunotherapeutic compounds, demonstrating significant investment in research and potential for growth in oncology and beyond.
Basic Stats
The share price of Immutep Limited as of 5 September 2025 is $0.24 / share. This is a decrease of 0.00% from the prior week. The market cap (or net worth) of Immutep Limited as of 5 September 2025 is $344.95 MM.
The Factor Analysis chart (below right) shows a view of Immutep Limited from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 344.95 MM |
| EV | 278.64 MM |
| Shares Out. | 1,460.39 MM |
| Earnings Date | |
| EPS (TTM) | -0.04 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | 33.91 MM |
| Short Float | 2.76 % |
| Days to Cover | 15.01 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 0.53 |
| Beta | 1.17 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | -5.61 |
| Price/Book | 2.40 |
| Price/TBV | 2.53 |
| Book/Market | 0.42 |
| EBIT/EV | -0.22 |
| EBIT(3yr avg)/EV | -0.17 |
| ROA | -0.30 |
| ROE | -0.32 |
| ROIC | -0.42 |
| CROIC | -0.65 |
| OCROIC | -0.43 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 69.29 /100 |
| Profitability | 4.67 /100 |
| Quality Score | 27.15 /100 |
| Value Score | 10.35 /100 |
| Momentum Score | 19.32 /100 |
| Stability (Low Vol) Score | 36.24 /100 |
| Analyst Sentiment | 82.82 /100 |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 0.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Immutep Limited is $1.21. The forecasts range from a low of $0.71 to a high of $2.20. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Immutep Limited. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2018-05-29 | Maxim Group | Buy | Buy | Maintains |
| 2023-04-14 | WILSONS | Overweight | Overweight | Maintains |
| 2023-04-05 | GOETZPARTNERS SECURITIES | Outperform | Outperform | Maintains |
| 2022-12-06 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2022-06-16 | TAYLOR COLLISON | Outperform | Outperform | Maintains |
| 2022-05-10 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2022-05-05 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2021-09-30 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2021-01-18 | TAYLOR COLLISON | Outperform | Outperform | Maintains |
| 2023-06-05 | WILSONS | Overweight | Overweight | Maintains |
| 2023-05-29 | GOETZPARTNERS SECURITIES | Outperform | Outperform | Maintains |
| 2023-05-24 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2022-06-15 | TAYLOR COLLISON | Outperform | Outperform | Maintains |
| 2022-05-09 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2022-05-04 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2021-09-29 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2021-01-17 | TAYLOR COLLISON | Outperform | Outperform | Maintains |
| 2023-08-30 | WILSONS | Overweight | Overweight | Maintains |
| 2023-07-02 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2023-12-22 | WILSONS | Overweight | Overweight | Maintains |
| 2023-10-31 | GOETZPARTNERS SECURITIES | Outperform | Outperform | Maintains |
| 2023-10-24 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2023-08-31 | WILSONS | Overweight | Overweight | Maintains |
| 2023-07-03 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2023-06-06 | WILSONS | Overweight | Overweight | Maintains |
| 2023-05-30 | GOETZPARTNERS SECURITIES | Outperform | Outperform | Maintains |
| 2023-05-25 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2024-08-07 | WILSONS | Overweight | Overweight | Maintains |
| 2024-07-14 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2024-02-25 | GOETZPARTNERS SECURITIES | Outperform | Outperform | Maintains |
| 2023-12-21 | WILSONS | Overweight | Overweight | Maintains |
| 2023-10-30 | GOETZPARTNERS SECURITIES | Outperform | Outperform | Maintains |
| 2023-10-23 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2025-01-06 | WILSONS | Overweight | Overweight | Maintains |
| 2024-12-11 | CANACCORD GENUITY | Buy | Buy | Maintains |
| 2024-11-14 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2025-04-07 | WILSONS | Overweight | Overweight | Maintains |
| 2025-03-05 | JEFFERIES | Buy | Buy | Maintains |
| 2025-03-05 | CANACCORD GENUITY | Buy | Buy | Maintains |
| 2025-07-16 | JEFFERIES | Buy | Buy | Maintains |
| 2025-06-22 | CANACCORD GENUITY | Buy | Buy | Maintains |
| 2025-05-05 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2025-07-17 | WILSONS | Overweight | Overweight | Maintains |
